## 15-ketoprostaglandin E (15-keto-PGE)
15-keto-PGE is a **metabolite** of **prostaglandin E2 (PGE2)**. It is produced in the body by the enzyme **15-hydroxyprostaglandin dehydrogenase (15-PGDH)**. While PGE2 is a potent mediator of inflammation and other biological processes, 15-keto-PGE is generally considered **inactive** in these processes.
Here's why 15-keto-PGE is important for research:
**1. Biomarker for PGE2 Activity:**
* 15-keto-PGE is a **stable and readily detectable metabolite** of PGE2. This makes it a valuable **biomarker** for assessing PGE2 activity in various biological samples, including urine, blood, and tissue.
* By measuring the levels of 15-keto-PGE, researchers can infer the activity of PGE2 in different biological systems. This information can be crucial for understanding the role of PGE2 in health and disease.
**2. Role in Biological Processes:**
* While 15-keto-PGE itself is generally inactive, its formation from PGE2 by 15-PGDH is an essential step in **deactivating PGE2**. This deactivation is critical for maintaining proper tissue homeostasis and preventing excessive inflammation.
* Some studies suggest that 15-keto-PGE may have some **independent biological effects**, particularly in the nervous system. However, these effects are less well-characterized compared to PGE2.
**3. Potential Therapeutic Targets:**
* The enzyme 15-PGDH, which converts PGE2 to 15-keto-PGE, has been identified as a potential target for therapeutic intervention in various diseases.
* **Modulating the activity of 15-PGDH** could potentially alter PGE2 levels and have beneficial effects in conditions like inflammation, cancer, and neurodegenerative diseases.
**4. Research Tools:**
* 15-keto-PGE is used as a **tool in research** to investigate the role of PGE2 in various biological systems.
* By studying the formation and metabolism of 15-keto-PGE, researchers gain insights into the regulation of PGE2 levels and the mechanisms underlying its biological effects.
Overall, 15-keto-PGE is an important metabolite of PGE2, serving as a useful biomarker, providing insight into PGE2 inactivation, and potentially offering therapeutic opportunities.
15-ketoprostaglandin E: RN given refers to unlabeled cpd(11alpha,13E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 5280710 |
| CHEBI ID | 15548 |
| SCHEMBL ID | 23352884 |
| MeSH ID | M0056984 |
| Synonym |
|---|
| 15-oxoprostaglandin e1 |
| unii-63fr527uj6 |
| prost-13-en-1-oic acid, 11-hydroxy-9,15-dioxo-, (11alpha,13e)- |
| 22973-19-9 |
| 63fr527uj6 , |
| 15-keto-pge |
| 15-keto pge1 |
| 15-ketoprostaglandin e1 |
| (13e)-11alpha-hydroxy-9,15-dioxoprost-13-en-1-oic acid |
| CHEBI:15548 |
| 9,15-dioxo-11r-hydroxy-13e-prostaenoic acid |
| 15-keto-prostaglandin e1 |
| 15-keto-pge1 |
| LMFA03010146 |
| C04654 |
| (13e)-11alpha-hydroxy-9,15-dioxoprost-13-enoate |
| 15-ketoprostaglandin e |
| 3-hydroxy-5-oxo-2-(3-oxo-1-octenyl)-cyclopentaneheptanoic acid |
| 15-oxo-pge1 |
| 7-[(1r,2r,3r)-3-hydroxy-5-oxo-2-[(e)-3-oxooct-1-enyl]cyclopentyl]heptanoic acid |
| 15-keto prostaglandin e1 |
| u-22409 |
| 7-((1r,2r,3r)-3-hydroxy-2-((1e)-3-oxooct-1-enyl)-5-oxocyclopentyl)heptanoic acid |
| alprostadil impurity c [ep impurity] |
| prost-13-en-1-oic acid, 11-hydroxy-9,15-dioxo-, (11.alpha.,13e)- |
| VXPBDCBTMSKCKZ-XQHNHVHJSA-N |
| 9,15-dioxo-11.alpha.-hydroxyprost-13e-en-1-oic acid |
| HMS3648D05 |
| J-014926 |
| (11a,13e)-11-hydroxy-9,15-dioxoprost-13-en-1-oate |
| 1-hydroxy-9,15-dioxo-(11a,13e)-prost-13-en-1-oic acid |
| (11alpha,13e)-11-hydroxy-9,15-dioxoprost-13-en-1-oate |
| (11alpha,13e)-11-hydroxy-9,15-dioxoprost-13-en-1-oic acid |
| (13e)-11-alpha-hydroxy-9,15-dioxoprost-13-enoic acid |
| 15-keto-pge1-alpha |
| 3-hydroxy-5-oxo-2-(3-oxo-1-octenyl)-cyclopentaneheptanoate |
| (13e)-11a-hydroxy-9,15-dioxoprost-13-enoic acid |
| (11a,13e)-11-hydroxy-9,15-dioxoprost-13-en-1-oic acid |
| 1-hydroxy-9,15-dioxo-(11a,13e)-prost-13-en-1-oate |
| 9,15-dioxo-11r-hydroxy-13e-prostaenoate |
| (13e)-11alpha-hydroxy-9,15-dioxoprost-13-enoic acid |
| 15-ketoprostaglandine1 |
| Q27098096 |
| sr-01000946407 |
| SR-01000946407-1 |
| SCHEMBL23352884 |
| 9,15-dioxo-11alpha-hydroxy-prost-13e-en-1-oic acid |
| DTXSID601216545 |
| PD021169 |
| Class | Description |
|---|---|
| prostaglandins E | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.97) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||